Inhibition of acute vascular thrombosis in chimpanzees by an antihuman tissue factor antibody targeting the factor X binding site

Thrombosis and Haemostasis

Volumn 103, Issue 1, 2010, Pages 224-233

  Jiao, Jin An ^a   Kelly, Andrew B ^b   Marzec, Ulla M ^a   Nieves, Esperanza ^a   Acevedo, Jorge ^a   Burkhardt, Martin ^a   Edwards, Ana ^a,c   Zhu, Xiao Yun ^a,c   Chavaillaz, Pierre Andre ^a   Wong, Alice ^a   Wong, Jeffrey L ^a,c   Egan, Jack O ^a,c   Taylor, Dean ^a,c   Rhode, Peter R ^a,c   Wong, Hing C ^a,c  

^a Sunol Molecular Corporation   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALTOR BIOSCIENCE CORPORATION   (United States)

Author keywords

Animal models; Arterial thrombosis; Coagulation inhibitors; Factor VII; Tissue factor

Indexed keywords

8 QUINOLINOL INDIUM IN 111; ALT 836; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BAGG ALBINO MOUSE; BINDING SITE; BLEEDING; BLEEDING TIME; BREAST CANCER; CANCER CELL CULTURE; CELL ADHESION; CHIMPANZEE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDARTERECTOMY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMORAL ARTERY; HEMOSTASIS; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCINTILLATION CAMERA; THROMBOCYTE COUNT; THROMBOGENESIS; VASCULAR PATENCY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BINDING SITES; BLOOD COAGULATION; BLOOD LOSS, SURGICAL; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDARTERECTOMY; FACTOR IX; FACTOR VIIA; FACTOR X; FEMALE; FEMORAL ARTERY; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; PAN TROGLODYTES; RECOMBINANT FUSION PROTEINS; THROMBOPLASTIN; THROMBOSIS;

EID: 74249099908     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-06-0400     Document Type: Article

References (55)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Harker LA, et al. Novel antithrombotic agents. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. J.P. Lippincott 1994; pp. 1638-1660.
3. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-1369.
4. Falk E, et al. Coronary plaque disruption. Circulation 1995; 92: 657-671.
5. Krishnaswamy S, Field KA, Edgington TS, et al. Role of the membrane surface in the activation of human coagulation factor X. J Biol Chem 1992; 267: 26110-26120.
6. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-806.
7. Harker LA, et al. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost 1997; 78: 736-741.
8. Weitz JI, et al. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 234S-256S.
9. Shirk RA, Vlasuk GP. Inhibitors of factor VIIa/tissue factor. Arterioscler Thromb Vasc Biol 2007; 27: 1895-1900.
10. Himber J, et al. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997; 78: 1142-1149.
11. Harker LA, et al. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26: 76-82.
12. Neuenschwander PF, Morrissey JH. Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIa Gla domain is dispensable for binding to tissue factor but important for activation of factor X. J Biol Chem 1994; 269: 8007-8013.
13. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol 2005; 25: 47-56.
14. Versteeg HH, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008; 111: 190-199.
15. Stinson JR, et al. Generation of single-chain antibody fragments by PCR. In: PCR Strategies. Academic Press, San Diego 1995; 300-312.
16. Broze GJ, Jr., et al. Purification of human brain tissue factor. J Biol Chem 1985; 260: 10917-10920.
17. Barenholz Y, et al. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977; 16: 2806-2810.
18. Neuenschwander PF, et al. Importance of substrate composition, pH and other variables on tissue factor enhancement of factor VIIa activity. Thromb Haemost 1993; 70: 970-977.
19. Broze GJ, Jr., et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-343.
20. Fair DS, MacDonald MJ. Cooperative interaction between factor VII and cell surface-expressed tissue factor. J Biol Chem 1987; 262: 11692-11698.
21. Lumsden AB, et al. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons. Blood 1993; 81: 1762-1770.
22. Kelly AB, et al. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-1012.
23. Harker LA, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87: 1833-1844.
24. Kotze HF, et al. Kinetics of In-111-platelets in the baboon: I. Isolation and labelling of a viable and representative platelet population. Thromb Haemost 1985; 53: 404-407.
25. Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-3188.
26. Suleymanov OD, et al. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: Comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J Pharmacol Exp Ther 2003; 306: 1115-1121.
27. Bom VJ, Bertina RM. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 1990; 265: 327-336.
28. Ruf W, et al. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991; 266: 16256.
29. Morrow DA, et al. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur Heart J 2005; 26: 682-68 8.
30. Welty-Wolf KE, et al. Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol 2006; 290: L21-31.
31. Bruggemann M, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987; 166: 1351-1361.
32. Steffel J, et al. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113: 722-731.
33. Kirchhofer D, et al. Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti-tissue factor antibodies. Thromb Haemost 2000; 84: 1072-1081.
34. Shaw AW, et al. The local phospholipid environment modulates the activation of blood clotting. J Biol Chem 2007; 282: 6556-6563.
35. Monroe DM, Key NS. The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost 2007; 5: 1097-1105.
36. Shobe J, et al. Macromolecular substrate affinity for the tissue factor-factor VIIa complex is independent of scissile bond docking. J Biol Chem 1999; 274: 24171-24175.
37. Ruf W, Edgington TS. An anti-tissue factor monoclonal antibody which inhibits TF:VIIa complex is a potent anticoagulant in plasma. Thrombosis and Haemostasis 1991; 66: 529-533.
38. Faelber K, et al. The 1.85 A resolution crystal structures of tissue factor in complex with humanized Fab D3h44 and of free humanized Fab D3h44: revisiting the solvation of antigen combining sites. J Mol Biol 2001; 313: 83-97.
39. Huang M, et al. The meachanism of inhibitory antibody on TF-initiated blood coagulation revealed by crystal structures of human tissue factor, Fab 5G9 and TF.G9 complex. J Mol Biol 1998; 275: 873-894.
40. Ohto U, et al. Crystal structure of a humanized Fab fragment of anti-tissue factor antibody in complex with tissue factor. J Synchrotron Radiat 2004; 11: 105-108.
41. Sambola A, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107: 973-977.
42. Felmeden DC, et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 2003; 92: 400-405.
43. Soejima H, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908-2913.
44. Ardissino D, et al. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349: 769-771.
45. Marmur JD, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-1232.
46. Giesen PL, Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost 2000; 26: 379-384.
47. Simak J, et al. Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J Thromb Haemost 2006; 4: 1296-1302.
48. Chironi GN, et al. Endothelial microparticles in diseases. Cell Tissue Res 2009; 335: 143-151.
49. Dignat-George F, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004; 91: 667-673.
50. Shet AS, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003; 102: 2678-2683.
51. Diamant M, et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-2447.
52. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004; 50: 187-196.
53. Butenas S, et al. Tissue factor activity in whole blood. Blood 2005; 105: 2764-2770.
54. Bogdanov VY, et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9: 458-462.
55. Erhardtsen E, et al. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects. J Clin Pharmacol 2001; 41: 880-885.